EXTON, Pa., Aug. 1 /PRNewswire-FirstCall/ -- Kensey Nash Corporation today announced that it will release its earnings results for its fourth quarter and fiscal year ended June 30, 2008 at 7:00 A.M. Eastern Time on Thursday, August 21, 2008.
Joe Kaufmann, President and CEO, will be hosting a teleconference discussing the earnings results on Thursday, August 21, 2008 at 9:00 A.M. Eastern Time.
To participate in the teleconference call, dial 612-332-0345. The teleconference call will also be available for replay starting Thursday, August 21, 2008 at 11:00 A.M. Eastern Time through Thursday, August 28, 2008 at 11:59 P.M. Eastern Time by dialing 1-800-475-6701 with an access code of 956292.
Individuals interested in listening to the teleconference may also do so over the Internet at http://www.kenseynash.com/. To listen to the live teleconference call, please go to the http://www.kenseynash.com/ website and choose the Investor Relations page. Please allow 15 minutes prior to the start of the call to register and download and/or install any necessary software. A replay of the teleconference will be archived on the http://www.kenseynash.com/ website and may be accessed following the teleconference.
About Kensey Nash Corporation. Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily in the sports medicine, spine, and endovascular markets. Many of the products are based on the Company's significant expertise in the design, development, manufacturing and processing of absorbable biomaterials, which has led to partnerships to commercialize technologies. Kensey Nash has also developed and commercialized a series of innovative endovascular products and recently announced the sale of this product line to Spectranetics, Inc. In conjunction with the sale transaction, the Company will continue to manufacture and develop these products for Spectranetics for a period of time. The Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.
